{
    "info": {
        "nct_id": "NCT03703167",
        "official_title": "Phase Ib Trial With Dose Expansion of the Bruton\"s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab and Lenalidomide in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",
        "inclusion_criteria": "* Participants must be able to understand and be willing to sign a written informed consent document.\n* Men and woman who are at least 18 years of age on the day of consenting to the study.\n* Histologically documented PCNSL or histologically documented systemic diffuse large B-cell lymphoma (DLBCL).\n* Patients must have relapsed/refractory PCNSL or relapsed/refractory SCNSL\n* All patients need to have received at least one prior CNS directed therapy. There is no restriction on the number of recurrences.\n* Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 21 days prior to study registration. For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings consistent with CSF disease 21 days prior to study registration (at the discretion of the investigator).\n* Participants must have an ECOG performance status of 0, 1, or 2.\n* Participants must have adequate bone marrow and organ function shown by:\n\n  * Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L\n  * Platelets ≥ 75 x 10^9/L and no platelet transfusion within the past 21 days prior to study registration\n  * Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 21 days prior to study registration\n  * International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal\n  * Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome.\n  * Serum creatinine ≤ 2 times the upper limit of normal\n  * Escalation: calculated creatinine clearance(CrCl) ≥ 60ml/min using the Cockcroft-Gault equation (Men: CrCl (min/ml) = (140-age) X (actual weight in kg) / 72 X serum creatinine (mg/dL); Women: CrCl (ml/min) = (140-age) X (actual weight in kg) X 0.85 / 72 X serum creatinine (mg/dL))\n  * Extension: calculated creatinine clearance(CrCl) ≥30ml/min using the Cockcroft-Gault equation (Men: CrCl (min/ml) = (140-age) X (actual weight in kg) / 72 X serum creatinine (mg/dL); Women: CrCl (ml/min) = (140-age) X (actual weight in kg) X 0.85 / 72 X serum creatinine (mg/dL))\n* Woman of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.\n* Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry. See section on Pregnancy and Reproduction.\n* Patients must be able to tolerate MRI/CT scans.\n* Patients must be able to tolerate lumbar puncture and/or Ommaya taps.\n* Participants must have recovered to grade 1 toxicity from prior therapy.\n* Participants should be able to submit up to 20 unstained formalin-fixed, paraffinembedded (FFPE) slides from the initial tissue diagnosis prior to study registration for confirmation of diagnosis and correlative studies\n* All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program.\n* Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.\n\nNOTE: Prior autologous stem cell transplant as well as prior radiation to the CNS does NOT prevent patients from enrollment into the trial.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded.\n* Patient is concurrently using other approved or investigational antineoplastic agents.\n* Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C prior to starting the study drug, or the patient has not recovered from the side effects of such therapy.\n* Patient has received external beam radiation therapy to the CNS within 21 days of the first dose of the study drug.\n* Patient requires more than 8 mg of dexamethasone daily or the equivalent\n* Patient has an active concurrent malignancy requiring active therapy\n* The patient has been treated with radio- or toxin-immunoconjugates within 70 days of the first dose of the study drug.\n* Patient is allergic to components of the study drug.\n* Patient is using warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists. Patients must be off warfarin-derivative anticoagulants for at least seven days prior to starting the study drug. Low molecular weight heparin is allowed. Patients with congenital bleeding diathesis are excluded.\n* Patient is taking a drug known to be a moderate and strong inhibitor or inducers of the P450 isoenzyme CYP3A. Participants must be off P450/CYP3A inhibitors and inducers for at least two weeks prior to starting the study drug.\n* Patient is using systemic immunosuppressant therapy, including cyclosporine A, tacrolimus, sirolimus, and other such medications, or chronic administration of > 5 mg/day or prednisone or the equivalent. Participants must be off immunosuppressant therapy for at least 28 days prior to the first dose of the study drug.\n* Patient has significant abnormalities on screening electrocardiogram (EKG) and active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, hypertension, valvular disease, pericarditis, or myocardial infarction within 6 months of screening,\n* Patient has a known bleeding diathesis (e.g. von Willebrand\"s disease) or hemophilia.\n* Patient is known to have human immunodeficiency virus (HIV) infection.\n* Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests.\n* Patient is known to have an uncontrolled active systemic infection.\n* Patient underwent major systemic surgery ≤ 4 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery, or who plan to have surgery within 2 weeks of the first dose of the study drug.\n* Patient is unable to swallow capsules or has a disease or condition significantly affecting gastrointestinal function, such as malabsorption syndrome, resection of the stomach or small bowel, or complete bowel obstruction.\n* Patient has poorly controlled diabetes mellitus with a glycosylated hemoglobin >8% or poorly controlled steroid-induced diabetes mellitus with a glycosylated hemoglobin of >8%. (for patients who received a short-term, high-dose dexamethasone treatment course prior to enrollment (<7 days), the HbA1c value can be rounded to the nearest whole number).\n* Patient has a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject\"s safety or put the study outcomes at undue risk.\n* Women who are pregnant or nursing (lactating), where pregnancy is defined as a state of a female after conception until the termination of gestation, confirmed by a positive serum hCG laboratory test of > 5 mIU/mL (See section on Pregnancy and Reproduction)\n* Patient has undergone prior allogenic stem cell transplant (autologous stem cell transplant is NOT an exclusion)\n* The patient is unwell or unable to participate in all required study evaluations and procedures\n* Known hypersensitivity to ibrutinib, thalidomide or lenalidomide\n* Females who are pregnant.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Men and woman who are at least 18 years of age on the day of consenting to the study.",
            "criterions": [
                {
                    "exact_snippets": "Men and woman who are at least 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have an ECOG performance status of 0, 1, or 2.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0, 1, or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically documented PCNSL or histologically documented systemic diffuse large B-cell lymphoma (DLBCL).",
            "criterions": [
                {
                    "exact_snippets": "Histologically documented PCNSL",
                    "criterion": "primary central nervous system lymphoma (PCNSL)",
                    "requirements": [
                        {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically documented systemic diffuse large B-cell lymphoma (DLBCL)",
                    "criterion": "systemic diffuse large B-cell lymphoma (DLBCL)",
                    "requirements": [
                        {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program.",
            "criterions": [
                {
                    "exact_snippets": "All study participants must be registered into the mandatory Revlimid REMS® program",
                    "criterion": "Revlimid REMS program registration",
                    "requirements": [
                        {
                            "requirement_type": "registration",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be willing and able to comply with the requirements of the REMS® program",
                    "criterion": "compliance with Revlimid REMS program requirements",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine ≤ 2 times the upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤ 2 times the upper limit of normal",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to tolerate lumbar puncture and/or Ommaya taps.",
            "criterions": [
                {
                    "exact_snippets": "able to tolerate lumbar puncture",
                    "criterion": "lumbar puncture",
                    "requirements": [
                        {
                            "requirement_type": "tolerability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "able to tolerate ... Ommaya taps",
                    "criterion": "Ommaya taps",
                    "requirements": [
                        {
                            "requirement_type": "tolerability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants should be able to submit up to 20 unstained formalin-fixed, paraffinembedded (FFPE) slides from the initial tissue diagnosis prior to study registration for confirmation of diagnosis and correlative studies",
            "criterions": [
                {
                    "exact_snippets": "able to submit up to 20 unstained formalin-fixed, paraffinembedded (FFPE) slides from the initial tissue diagnosis prior to study registration",
                    "criterion": "FFPE slides from initial tissue diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 20,
                                "unit": "slides"
                            }
                        },
                        {
                            "requirement_type": "staining status",
                            "expected_value": "unstained"
                        },
                        {
                            "requirement_type": "fixation method",
                            "expected_value": [
                                "formalin-fixed",
                                "paraffin-embedded"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to study registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "for confirmation of diagnosis and correlative studies",
                    "criterion": "FFPE slides from initial tissue diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "purpose",
                            "expected_value": [
                                "confirmation of diagnosis",
                                "correlative studies"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All patients need to have received at least one prior CNS directed therapy. There is no restriction on the number of recurrences.",
            "criterions": [
                {
                    "exact_snippets": "All patients need to have received at least one prior CNS directed therapy.",
                    "criterion": "prior CNS directed therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "There is no restriction on the number of recurrences.",
                    "criterion": "number of recurrences",
                    "requirements": [
                        {
                            "requirement_type": "restriction",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have adequate bone marrow and organ function shown by:",
            "criterions": [
                {
                    "exact_snippets": "adequate bone marrow and organ function",
                    "criterion": "bone marrow and organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "NOTE: Prior autologous stem cell transplant as well as prior radiation to the CNS does NOT prevent patients from enrollment into the trial.",
            "criterions": [
                {
                    "exact_snippets": "Prior autologous stem cell transplant ... does NOT prevent patients from enrollment into the trial.",
                    "criterion": "prior autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior radiation to the CNS does NOT prevent patients from enrollment into the trial.",
                    "criterion": "prior radiation to the CNS",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to tolerate MRI/CT scans.",
            "criterions": [
                {
                    "exact_snippets": "Patients must be able to tolerate MRI/CT scans",
                    "criterion": "tolerance to MRI/CT scans",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.",
            "criterions": [
                {
                    "exact_snippets": "Females of reproductive potential",
                    "criterion": "reproductive potential (female)",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program",
                    "criterion": "adherence to scheduled pregnancy testing",
                    "requirements": [
                        {
                            "requirement_type": "adherence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "program",
                            "expected_value": "Revlimid REMS"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "International Normalized Ratio (INR) ≤ 1.5",
                    "criterion": "International Normalized Ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "PTT (aPTT) ≤ 1.5 times the upper limit of normal",
                    "criterion": "PTT (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Escalation: calculated creatinine clearance(CrCl) ≥ 60ml/min using the Cockcroft-Gault equation (Men: CrCl (min/ml) = (140-age) X (actual weight in kg) / 72 X serum creatinine (mg/dL); Women: CrCl (ml/min) = (140-age) X (actual weight in kg) X 0.85 / 72 X serum creatinine (mg/dL))",
            "criterions": [
                {
                    "exact_snippets": "calculated creatinine clearance(CrCl) ≥ 60ml/min using the Cockcroft-Gault equation",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "calculated value (Cockcroft-Gault equation)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have relapsed/refractory PCNSL or relapsed/refractory SCNSL",
            "criterions": [
                {
                    "exact_snippets": "relapsed/refractory PCNSL",
                    "criterion": "PCNSL (Primary Central Nervous System Lymphoma)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed/refractory SCNSL",
                    "criterion": "SCNSL (Secondary Central Nervous System Lymphoma)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Extension: calculated creatinine clearance(CrCl) ≥30ml/min using the Cockcroft-Gault equation (Men: CrCl (min/ml) = (140-age) X (actual weight in kg) / 72 X serum creatinine (mg/dL); Women: CrCl (ml/min) = (140-age) X (actual weight in kg) X 0.85 / 72 X serum creatinine (mg/dL))",
            "criterions": [
                {
                    "exact_snippets": "calculated creatinine clearance(CrCl) ≥30ml/min using the Cockcroft-Gault equation",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 21 days prior to study registration",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin (Hgb) ≥ 8 g/dL",
                    "criterion": "hemoglobin (Hgb) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no red blood cell (RBC) transfusion within the past 21 days prior to study registration",
                    "criterion": "red blood cell (RBC) transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": "no transfusion within the past 21 days prior to study registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry. See section on Pregnancy and Reproduction.",
            "criterions": [
                {
                    "exact_snippets": "Female subjects of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative plasma pregnancy test upon study entry",
                    "criterion": "plasma pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "upon study entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥ 75 x 10^9/L and no platelet transfusion within the past 21 days prior to study registration",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 75 x 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no platelet transfusion within the past 21 days prior to study registration",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": "no transfusion within 21 days prior to study registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 3 times the upper limit of normal",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must be able to understand and be willing to sign a written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "Participants must be able to understand",
                    "criterion": "ability to understand",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be willing to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome.",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin ≤ 1.5 times the upper limit of normal",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "patients with well documented Gilbert Syndrome"
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin within the normal range in patients with well documented Gilbert Syndrome",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within the normal range"
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "patients with well documented Gilbert Syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have recovered to grade 1 toxicity from prior therapy.",
            "criterions": [
                {
                    "exact_snippets": "recovered to grade 1 toxicity from prior therapy",
                    "criterion": "toxicity from prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Woman of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.",
            "criterions": [
                {
                    "exact_snippets": "Woman of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug.",
                    "criterion": "use of highly effective birth control (women of reproductive potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "during the period of therapy",
                                "for 30 days after the last dose of the study drug"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.",
                    "criterion": "use of highly effective contraception (sexually active men)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "during the period of therapy",
                                "for 3 months after the last dose"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 21 days prior to study registration. For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings consistent with CSF disease 21 days prior to study registration (at the discretion of the investigator).",
            "criterions": [
                {
                    "exact_snippets": "Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 21 days prior to study registration.",
                    "criterion": "parenchymal lesion disease progression",
                    "requirements": [
                        {
                            "requirement_type": "evidence of progression on imaging",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": [
                                "MRI of the brain",
                                "head CT"
                            ]
                        },
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells ... 21 days prior to study registration",
                    "criterion": "CSF cytology for lymphoma cells",
                    "requirements": [
                        {
                            "requirement_type": "presence of lymphoma cells",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients with leptomeningeal disease only, ... imaging findings consistent with CSF disease 21 days prior to study registration (at the discretion of the investigator).",
                    "criterion": "imaging findings consistent with CSF disease",
                    "requirements": [
                        {
                            "requirement_type": "imaging findings consistent with CSF disease",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Females who are pregnant.",
            "criterions": [
                {
                    "exact_snippets": "Females who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Females",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded.",
            "criterions": [
                {
                    "exact_snippets": "Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded.",
                    "criterion": "SCNSL patients receiving treatment for extra-CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "actively receiving treatment for extra-CNS disease"
                        },
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has received external beam radiation therapy to the CNS within 21 days of the first dose of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "received external beam radiation therapy to the CNS within 21 days of the first dose of the study drug",
                    "criterion": "external beam radiation therapy to the CNS",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "relative_to_event",
                            "expected_value": "first dose of the study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a known bleeding diathesis (e.g. von Willebrand\"s disease) or hemophilia.",
            "criterions": [
                {
                    "exact_snippets": "known bleeding diathesis (e.g. von Willebrand\"s disease)",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hemophilia",
                    "criterion": "hemophilia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is unable to swallow capsules or has a disease or condition significantly affecting gastrointestinal function, such as malabsorption syndrome, resection of the stomach or small bowel, or complete bowel obstruction.",
            "criterions": [
                {
                    "exact_snippets": "Patient is unable to swallow capsules",
                    "criterion": "ability to swallow capsules",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "disease or condition significantly affecting gastrointestinal function",
                    "criterion": "gastrointestinal function",
                    "requirements": [
                        {
                            "requirement_type": "functionality",
                            "expected_value": "not significantly affected"
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "resection of the stomach or small bowel",
                    "criterion": "resection of the stomach or small bowel",
                    "requirements": [
                        {
                            "requirement_type": "history of resection",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "complete bowel obstruction",
                    "criterion": "complete bowel obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C prior to starting the study drug, or the patient has not recovered from the side effects of such therapy.",
            "criterions": [
                {
                    "exact_snippets": "Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C prior to starting the study drug",
                    "criterion": "prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last chemotherapy, monoclonal antibodies, or targeted anticancer therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time since last nitrosourea or mitomycin-C",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the patient has not recovered from the side effects of such therapy",
                    "criterion": "recovery from side effects of prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests.",
            "criterions": [
                {
                    "exact_snippets": "history of active or chronic infection with hepatitis C virus (HCV) ... as determined by serologic tests",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history of infection",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "infection status",
                            "expected_value": [
                                "active",
                                "chronic"
                            ]
                        },
                        {
                            "requirement_type": "determination method",
                            "expected_value": "serologic tests"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of active or chronic infection with ... hepatitis B virus (HBV) as determined by serologic tests",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history of infection",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "infection status",
                            "expected_value": [
                                "active",
                                "chronic"
                            ]
                        },
                        {
                            "requirement_type": "determination method",
                            "expected_value": "serologic tests"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is taking a drug known to be a moderate and strong inhibitor or inducers of the P450 isoenzyme CYP3A. Participants must be off P450/CYP3A inhibitors and inducers for at least two weeks prior to starting the study drug.",
            "criterions": [
                {
                    "exact_snippets": "Patient is taking a drug known to be a moderate and strong inhibitor or inducers of the P450 isoenzyme CYP3A",
                    "criterion": "use of moderate or strong inhibitors or inducers of CYP3A",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must be off P450/CYP3A inhibitors and inducers for at least two weeks prior to starting the study drug",
                    "criterion": "use of P450/CYP3A inhibitors and inducers",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The patient has been treated with radio- or toxin-immunoconjugates within 70 days of the first dose of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "treated with radio- or toxin-immunoconjugates within 70 days of the first dose of the study drug",
                    "criterion": "treatment with radio-immunoconjugates",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 70,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "treated with radio- or toxin-immunoconjugates within 70 days of the first dose of the study drug",
                    "criterion": "treatment with toxin-immunoconjugates",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 70,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has poorly controlled diabetes mellitus with a glycosylated hemoglobin >8% or poorly controlled steroid-induced diabetes mellitus with a glycosylated hemoglobin of >8%. (for patients who received a short-term, high-dose dexamethasone treatment course prior to enrollment (<7 days), the HbA1c value can be rounded to the nearest whole number).",
            "criterions": [
                {
                    "exact_snippets": "poorly controlled diabetes mellitus with a glycosylated hemoglobin >8%",
                    "criterion": "diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        },
                        {
                            "requirement_type": "glycosylated hemoglobin (HbA1c)",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "poorly controlled steroid-induced diabetes mellitus with a glycosylated hemoglobin of >8%",
                    "criterion": "steroid-induced diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        },
                        {
                            "requirement_type": "glycosylated hemoglobin (HbA1c)",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients who received a short-term, high-dose dexamethasone treatment course prior to enrollment (<7 days), the HbA1c value can be rounded to the nearest whole number",
                    "criterion": "short-term, high-dose dexamethasone treatment course prior to enrollment",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "HbA1c rounding",
                            "expected_value": "can be rounded to the nearest whole number"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is allergic to components of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "Patient is allergic to components of the study drug",
                    "criterion": "allergy to study drug components",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to ibrutinib, thalidomide or lenalidomide",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to ibrutinib",
                    "criterion": "hypersensitivity to ibrutinib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... thalidomide",
                    "criterion": "hypersensitivity to thalidomide",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... lenalidomide",
                    "criterion": "hypersensitivity to lenalidomide",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is concurrently using other approved or investigational antineoplastic agents.",
            "criterions": [
                {
                    "exact_snippets": "concurrently using other approved or investigational antineoplastic agents",
                    "criterion": "use of other antineoplastic agents",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent type",
                            "expected_value": [
                                "approved",
                                "investigational"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has significant abnormalities on screening electrocardiogram (EKG) and active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, hypertension, valvular disease, pericarditis, or myocardial infarction within 6 months of screening,",
            "criterions": [
                {
                    "exact_snippets": "significant abnormalities on screening electrocardiogram (EKG)",
                    "criterion": "screening electrocardiogram (EKG) abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "active and significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled or symptomatic arrhythmias",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "valvular disease",
                    "criterion": "valvular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pericarditis",
                    "criterion": "pericarditis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within 6 months of screening",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "relative_to",
                            "expected_value": "screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has an active concurrent malignancy requiring active therapy",
            "criterions": [
                {
                    "exact_snippets": "active concurrent malignancy",
                    "criterion": "concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring active therapy",
                    "criterion": "concurrent malignancy therapy",
                    "requirements": [
                        {
                            "requirement_type": "therapy requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is using warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists. Patients must be off warfarin-derivative anticoagulants for at least seven days prior to starting the study drug. Low molecular weight heparin is allowed. Patients with congenital bleeding diathesis are excluded.",
            "criterions": [
                {
                    "exact_snippets": "Patient is using warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists. Patients must be off warfarin-derivative anticoagulants for at least seven days prior to starting the study drug.",
                    "criterion": "use of warfarin-derivative anticoagulants or vitamin K antagonists",
                    "requirements": [
                        {
                            "requirement_type": "absence for at least seven days prior to starting the study drug",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Low molecular weight heparin is allowed.",
                    "criterion": "use of low molecular weight heparin",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with congenital bleeding diathesis are excluded.",
                    "criterion": "congenital bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are pregnant or nursing (lactating), where pregnancy is defined as a state of a female after conception until the termination of gestation, confirmed by a positive serum hCG laboratory test of > 5 mIU/mL (See section on Pregnancy and Reproduction)",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant ... pregnancy is defined as a state of a female after conception until the termination of gestation",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing (lactating)",
                    "criterion": "nursing (lactating) status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed by a positive serum hCG laboratory test of > 5 mIU/mL",
                    "criterion": "serum hCG laboratory test result",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "mIU/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is known to have an uncontrolled active systemic infection.",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled active systemic infection",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient requires more than 8 mg of dexamethasone daily or the equivalent",
            "criterions": [
                {
                    "exact_snippets": "requires more than 8 mg of dexamethasone daily or the equivalent",
                    "criterion": "dexamethasone (or equivalent corticosteroid) daily dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "mg"
                            }
                        },
                        {
                            "requirement_type": "frequency",
                            "expected_value": "daily"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is known to have human immunodeficiency virus (HIV) infection.",
            "criterions": [
                {
                    "exact_snippets": "Patient is known to have human immunodeficiency virus (HIV) infection.",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The patient is unwell or unable to participate in all required study evaluations and procedures",
            "criterions": [
                {
                    "exact_snippets": "The patient is unwell",
                    "criterion": "patient wellness",
                    "requirements": [
                        {
                            "requirement_type": "wellness status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to participate in all required study evaluations and procedures",
                    "criterion": "ability to participate in study evaluations and procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient underwent major systemic surgery ≤ 4 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery, or who plan to have surgery within 2 weeks of the first dose of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "underwent major systemic surgery ≤ 4 weeks prior to starting the trial treatment",
                    "criterion": "major systemic surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has not recovered from the side effects of such surgery",
                    "criterion": "recovery from side effects of major systemic surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "plan to have surgery within 2 weeks of the first dose of the study drug",
                    "criterion": "planned surgery",
                    "requirements": [
                        {
                            "requirement_type": "planned time to surgery",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has undergone prior allogenic stem cell transplant (autologous stem cell transplant is NOT an exclusion)",
            "criterions": [
                {
                    "exact_snippets": "Patient has undergone prior allogenic stem cell transplant",
                    "criterion": "prior allogenic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autologous stem cell transplant is NOT an exclusion",
                    "criterion": "prior autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is using systemic immunosuppressant therapy, including cyclosporine A, tacrolimus, sirolimus, and other such medications, or chronic administration of > 5 mg/day or prednisone or the equivalent. Participants must be off immunosuppressant therapy for at least 28 days prior to the first dose of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "Patient is using systemic immunosuppressant therapy, including cyclosporine A, tacrolimus, sirolimus, and other such medications",
                    "criterion": "systemic immunosuppressant therapy use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic administration of > 5 mg/day or prednisone or the equivalent",
                    "criterion": "chronic prednisone (or equivalent) administration",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must be off immunosuppressant therapy for at least 28 days prior to the first dose of the study drug",
                    "criterion": "immunosuppressant therapy discontinuation period",
                    "requirements": [
                        {
                            "requirement_type": "duration off therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Patient has a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject\"s safety or put the study outcomes at undue risk.",
            "criterions": [
                {
                    "exact_snippets": "life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "life-threatening illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "risk to safety or study outcomes (per investigator judgment)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "risk to safety or study outcomes (per investigator judgment)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "risk to safety or study outcomes (per investigator judgment)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}